top of page

Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC

  • Apr 13
  • 1 min read

CEO Cameron Turtle walks us through the data, shares his opinion on its translatability to part B of the current study, and tells us what else is ahead for Spyre.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page